| apixaban versus placebo | |||
| APPRAISE 2, 2011 NCT00831441 | apixaban 5mg twice daily versus placebo | patients with a recent acute coronary syndrome and at least two additional risk factors for recurrent ischemic events | double blind Follow-up duration: 8 months 39 countries |
| APPRAISE-1 (10mg od), 2009 NCT00313300 | apixaban 10 mg once daily versus placebo | patients with a recent ST-elevation or non–ST-elevation acute coronary syndrome(<7 days) | double blind Follow-up duration: 6 months Europe, Middle East, North America |
| APPRAISE-1 (2.5 mg bid), 2009 NCT00313300 | Apixaban 2.5mg twice daily
versus placebo | patients with a recent ST-elevation or non–ST-elevation acute coronary syndrome(<7 days) | double blind Follow-up duration: 6 months Europe, Middle East, North America |
| Argatroban versus heparin | |||
| ARGAMI-2, 1998 | Argatroban 60–20 mg/kg bolus; 2–4 µg /kg/min infusion for 72h versus UFH 5000 IU bolus; 1000 IU/h infusion | AMI | Follow-up duration: 30 days |
| ASA high dose versus ASA low dose | |||
| CURRENT - OASIS 7 (ASA), 2010 NCT00335452 | High-dose aspirin
versus Low-dose aspirin | ACS patients referred for an invasive strategy (scheduled for percutaneous coronary intervention no more than 72 hours after randomization) | open Follow-up duration: 30 days |
| aspirin versus control | |||
| ATACS-pilot, 1990 | Aspirin 80mg/d (Heparin + Warfarin) versus full-dose heparin followed by warfarin | acute coronary syndromes | Follow-up duration: 3m |
| aspirin versus placebo | |||
| VA-main, 1983 | Aspirin 324mg/d versus placebo | men with unstable angina | double blind Follow-up duration: 3m |
| VA-pilot, 0 | Aspirin 324 mg/d versus | Follow-up duration: 3m | |
| RISC, 1990 | Aspirin 75mg/d versus placebo | men with unstable coronary artery disease (unstable angina or non-Q wave myocardial infarction | double blind Follow-up duration: 12m Sweden |
| Canadian (Aspirin vs PBO), 1985 | Aspirin 1300mg/d versus placebo | patients with unstable angina | double blind Follow-up duration: 18m |
| ALDUSA-pilot, 0 | Aspirin 325mg/d, Aspirin 40mg/d versus | Follow-up duration: 12m | |
| Théroux, 1988 | Aspirin 325 mg twice daily versus placebo | acute unstable angina | double blind Follow-up duration: 6d (3m) |
| aspirin + dipyridamol versus placebo | |||
| Prandoni, 1991 | Aspirin 50mg/d + Dipyridamol 400mg/d versus placebo | patients with acute unstable angina | double blind Follow-up duration: 12m |
| aspirin + sulfinpyrazone versus placebo | |||
| Canadian (Aspirin + sulfinpyrazone), 1985 | Aspirin 1300mg/d + sulfinpyrazone 800mg/d versus placebo | patients with unstable angina | double blind Follow-up duration: 18m |
| atopaxar versus placebo | |||
| LANCELOT ACS, | 400-mg loading dose of atopaxar followed by a daily dose of 50 mg, 100 mg, or 200 mg for 12 weeks versus placebo | unstable-angina or non-STEMI patients | |
| J-LANCELOT, 2010 | atopaxar at a loading dose of 400 mg followed by 50 mg per day, 100 mg per day, or 200 mg per day for 12 weeks versus atopaxar at a loading dose of 400 mg followed by placebo | patients with acute coronary syndrome (unstable angina and NSTEMI) | Japan |
| bivalirudin versus eptifibatide + heparin | |||
| PROTECT-TIMI 30, 2006 NCT00250471 | bivalirudin alone versus eptifibatide plus either unfractionated heparin or enoxaparin | non ST elevation ACS patients undergoing PCI | open Follow-up duration: hospital stay International |
| bivalirudin versus heparin | |||
| HERO, 1997 | Bivalirudin 0.125–0.250 mg/kg bolus; 0.125–0.500 mg /kg/min infusion for 72h versus UFH 5000 IU bolus; 1000–1200 IU/h infusion | AMI (patients presenting within 12 hours with ST-segment elevation) | double blind Follow-up duration: 35 days |
| BAT (Bittl), 1995 | Bivalirudin 1.0 mg/kg bolus; 2.5 mg /kg/h for 4 h, then 0.2 mg /kg/h infusion for 24h versus UFH 175 IU/kg bolus; 15 IU mg /kg/h infusion | patients undergoing angioplasty for unstable or postinfarction angina | double blind Follow-up duration: 6 months North America and Europe |
| clopidogrel + aspirin versus aspirin | |||
| CURE, 2001 | clopidogrel 300 mg immediately, followed by 75 mg once daily + aspirin for 3 to 12 months versus aspirin (+placebo) | acute coronary syndromes without ST-segment elevation within 24 hours after the onset of symptoms | double blind Follow-up duration: NA (median <9 months) 28 countries |
| clopidogrel high-dose regimen versus clopidogrel standard-dose | |||
| CURRENT OASIS 7 (clopidogrel), 2010 NCT00335452 | Double-dose clopidogrel versus Standard-dose clopidogrel | ACS patients referred for an invasive strategy (scheduled for percutaneous coronary intervention no more than 72 hours after randomization) | open Follow-up duration: 30 days |
| coumadin versus aspirin | |||
| ASPECT-2 (coumadin vs aspirin), 2002 | coumadin (phenprocoumon or acenocoumarol) target INR 3-4)
versus aspirin 80mg daily | UA, AMI | open Follow-up duration: 1 year (range 0-26 months) the Netherlands |
| coumadin versus control (on top of aspirin) | |||
| ASPECT-2 (coumadin+asp vs asp), 2002 | coumadin(INR mean 2.4) +aspirin versus aspirin | UA, AMI | open Follow-up duration: 1 year the Netherlands |
| dalteparin versus placebo (on top of aspirin) | |||
| FRIC prolonged treatment phase (LWMH vs PBO), 1997 | dalteparin SC 120 i.u./kg twice-daily for 6 days followed by dalteparin 7500UI daily up to day 45 (+aspirin) versus unfractionated heparin dose-adjusted intravenous infusion (for at least 48h) then by subcutaneous injection up to day 6 (then placebo) (+aspirin) | Patients with unstable angina or non-Q-wave myocardial infarction | double blind Follow-up duration: 45 days |
| FRISC (long term), 1996 | dalteparin SC 120 IU per kg bodyweight [maximum 10 000 IU] twice daily for 6 days with 7500 IU once daily for 34-45 days +aspirin versus matched placebo + aspirin | patients with unstable CAD (unstable angina or non-Q-wave myocardial infarction) within the previous 72 hours | double blind Follow-up duration: 40 days Sweden |
| FRISC (short term), 1996 | dalteparin SC 120 IU per kg bodyweight [maximum 10 000 IU] twice daily for 6 days with 7500 IU once daily for 34-45 days +aspirin
versus matched placebo + aspirin | patients with unstable CAD (unstable angina or non-Q-wave myocardial infarction) within the previous 72 hours | double blind Follow-up duration: 6 days Sweden |
| dalteparin versus UFH (on top of aspirin) | |||
| FRIC (acute phase LMWH vs UFH), 1997 | twice-daily weight-adjusted subcutaneous injections of dalteparin (120 i.u./kg) (+aspirin)
versus dose-adjusted intravenous infusion of unfractionated heparin (+aspirin) | Patients with unstable angina or non-Q-wave myocardial infarction | open Follow-up duration: 6 days |
| Efegatran versus heparin | |||
| Klootwijk, 1999 | Efegatran 0.1–0.3 mg/kg bolus; 0.105–1.200 mg /kg/h infusion for 48h versus UFH 5000 IU bolus; 1000 IU/h infusion | patients with unstable angina | open Follow-up duration: 30 days |
| enoxaparin versus tinzaparin | |||
| EVET, 2005 | enoxaparin, 100 IU/kg subcutaneously twice daily +aspirin for 7 days versus tinzaparin, 175 IU/kg subcutaneously once daily +aspirin for 7 days | patients with non-ST-segment elevation acute coronary syndromes | open Follow-up duration: 30 days |
| enoxaparin versus UFH (on top of aspirin) | |||
| ESSENCE, 1997 | enoxaparin 1mg/kg, twice daily during 48h-8days versus continuous intravenous unfractionated heparin | patients with angina at rest or non–Q-wave myocardial infarction | Double blind Follow-up duration: 14 days (30 days) United states, Canada, South America, Europe |
| INTERACT, 2006 | enoxaparin (1 mg/kg subcutaneously twice daily) for 48 hours (+eptifibatide and aspirin) versus intravenous UFH (70 U/kg bolus followed by 15 U/kg per hour adjusted to an activated partial thromboplastin time of 1.5-2 times control) for 48 hours (+eptifibatide and aspirin) | high-risk patients with ACS receiving aspirin and eptifibatide | open Follow-up duration: 30 days (2.5y) Canada |
| SYNERGY, 2005 NCT00043784 | Enoxaparin 1 mg/kg twice daily versus unfractionated heparin | high-risk patients with acute coronary syndromes | open Follow-up duration: 30 days 12 countries |
| TIMI 11 B (long term), 1998 | enoxaprin during both the acute phase (IV) and outpatient phase (SC)
versus intravenous UFH for >=3 days (followed by subcutaneous placebo injections) | unstable angina/non–Q-wave myocardial infarction | double blind Follow-up duration: 43 days North America, South America, |
| TIMI 11 B (short term), 1998 | enoxaprin during both the acute phase and outpatient phase versus intravenous UFH for >=3 days (followed by subcutaneous placebo injections) | unstable angina/non–Q-wave myocardial infarction | double blind Follow-up duration: 8 days (43 days) North America, South America, |
| enoxaparin versus unfractionated heparin | |||
| RESCUE, NCT00077818 | Enoxaparin versus unfractionated heparin | patients diagnosed with acute coronary syndrome in the emergency department | open Follow-up duration: 30 days |
| fondaparinux versus enoxaparin | |||
| OASIS 5, 2006 NCT00139815 | fondaparinux 2.5 mg daily until hospital discharge or for up
to eight days versus enoxaparin 1 mg per kilogram of body weight twice daily for two to eight days or until the patient was in clinically stable condition | patients with acute coronary syndromes | double blind Follow-up duration: 9 days (180 days) 41 countires |
| PENTUA, 2004 | Four doses fondaparinux (2.5, 4, 8, or 12 mg once daily) for three to seven days versus enoxaparin (1 mg/kg twice daily) for three to seven days | patients with ACS without persistent ST-segment elevation | Follow-up duration: 9 days |
| Hirudin versus heparin | |||
| HIT-4, 1999 | Hirudin 0.2 mg/kg bolus; 0.5 mg/kg twice daily 0.1 mg/kg 0.1 mg /kg/h infusion for 5-7 days versus Placebo bolus, UFH 12 500 IU twice daily | patients with AMI <=6 h were treated with aspirin and streptokinase | double blind Follow-up duration: 30 days |
| OASIS, 1997 | low-dose hirudin (0.2 mg/kg bolus+0.10 mg/kg/h infusion) or medium-dose hirudin (0.4 mg/kg bolus+0.15 mg/kg/h infusion) for 72h versus heparin 5000 IU bolus+1000 to 1200 U/h | patients with unstable angina or suspected acute MI without ST-segment elevation | open Follow-up duration: 7 days |
| TIMI 9B, 1996 | Hirudin 0.1 mg/kg bolus; 0.1 mg /kg/h infusion for 96h versus UFH 5000 IU bolus; 1000 IU/h infusion | Unstable angina or AMI | open Follow-up duration: 30 days |
| GUSTO IIB, 1996 | Hirudin 0.1 mg/kg bolus; 0.1 mg /kg/h infusion for 72h versus UFH 5000 IU bolus; 1000 IU/h infusion for 72H | patients with acute coronary syndromes | open Follow-up duration: 30days (1 year) |
| OASIS pilot, 1997 | Hirudin 0.2–0.4 mg/kg bolus; 0.10–0.15 mg /kg/h infusion for 72h versus UFH 5000 IU bolus; 1000–1200 IU/h infusion | patients with unstable angina or suspected acute MI without ST-segment elevation | open Follow-up duration: 6 months |
| OASIS 2, 1999 | Hirudin 0.4 mg/kg bolus; 0.15 mg /kg/h infusion for 72h versus UFH 5000 IU bolus; 15 IU /kg/h infusion | patients with unstable angina or suspected acute myocardial infarction without ST elevation | double blind Follow-up duration: 7 days (6 months) |
| HELVETICA (Serruys), 1995 | Hirudin 40 mg intravenous bolus; 0.2 mg /kg/h infusion for 24 h, then 40 mg or placebo twice daily for 72h versus UFH 10 000 IU bolus; 15 IU /kg/h infusion for 24 h, then placebo twice daily | patients with unstable angina who were scheduled for angioplasty | double blind Follow-up duration: 6 months |
| Inogatran versus heparin | |||
| TRIM, 1997 | Inogatran 0.1–5.5 mg bolus; 2.0–10.0 mg/h infusion for 72h versus UFH 5000 IU bolus; 1200 IU/h infusion | patients with suspected unstable angina, or non-Q wave myocardial infarction | double blind Follow-up duration: 30 days |
| LMWH versus placebo (on top of aspirin) | |||
| Gurfinkel (LMWH+asp vs asp), 1995 | aspirin plus low molecular weight heparin (214 UIC/kg anti-Xa twice daily subcutaneously versus aspirin (200 mg/day | patients with unstable angina | single blind Follow-up duration: 5-7 days |
| LMWH versus UFH (on top of aspirin) | |||
| Gurfinkel (LMWH+asp vs UFH+asp), 1995 | aspirin plus low molecular weight heparin (214 UIC/kg anti-Xa twice daily subcutaneously versus aspirin plus regular heparin (400 IU/kg body weight per day intravenously and titered by activated partial thromboplastin time | patients with unstable angina | single blind Follow-up duration: 5-7 days |
| nadroparin versus UFH (on top of aspirin) | |||
| FRAXIS (14 days), 1998 | nadroparin for 14 days
versus unfractionated heparin for 14 days | unstable angina or non-Q wave myocardial infraction | double blind Follow-up duration: 14 days 17 countries |
| FRAXIS (6days), 1998 | nadroparin for 6 days (+aspirin) versus unfractionated heparin for 6 days (+aspirin) | unstable angina or non-Q wave myocardial infraction | Double blind Follow-up duration: 14 days 17 countries |
| otamixaban versus unfractionated heparin | |||
| SEPIA-ACS1 TIMI 42, 2009 NCT00317395 | otamixaban 5 doses (0·08 mg/kg bolus followed by 0.035, 0.070, 0.105, 0.140, 0.175 mg/kg/h) versus Heparin+eptifibatide | patients with non-ST-elevation acute coronary syndromes | double blind Follow-up duration: 7 days 36 countries |
| prasugrel versus clopidogrel | |||
| TRILOGY ACS (overall population), 2012 NCT00699998 | prasugrel 10 mg daily versus clopidogrel 75 mg daily | patients with acute coronary syndromes selected for a final treatment strategy of medical management without revascularization within 10 days after the index event | double-blind Follow-up duration: 17 months (median) 52 countries |
| TRITON-TIMI 38, 2007 NCT00097591 | prasugrel 60-mg loading dose
and 10-mg daily maintenance dose, for 6 to 15 months versus clopidogrel (a 300-mg loading dose and a 75-mg daily maintenance dose) for 6 to 15 months | patients with moderate-to-high-risk acute coronary syndromes (UA, NSTEMI,STEMI) with scheduled percutaneous coronary intervention | double blind 30 countries |
| rivaroxaban 2.5mg versus placebo | |||
| ATLAS ACS 2 - TIMI 51 (2.5mg), 2011 NCT00809965 | rivaroxaban 2.5 mg twice daily in addition to standard care versus placebo | patients with a recent ACS | double blind Follow-up duration: 13 months 44 countries |
| rivaroxaban 5mg versus placebo | |||
| ATLAS ACS 2 - TIMI 51 (5mg), 2011 NCT00809965 | rivaroxaban 5 mg twice daily in addition to standard care
versus placebo | patients with a recent ACS | double blind Follow-up duration: 13 months 44 countries |
| sulfinpyrazone versus placebo | |||
| Canadian (sulfinpyrazone alone), 1985 | sulfinpyrazone 800mg/d
versus placebo | patients with unstable angina | double blind Follow-up duration: 18m |
| ticagrelor versus clopidogrel | |||
| PLATO, 2009 NCT00391872 | ticagrelor 90mg twice daily versus clopidogrel 75mg once daily | patients with an acute coronary syndrome, with or without ST-segment elevation (onset of symptoms within the previous 24h). | double blind Follow-up duration: 1 y 43 countries |
| DISPERSE-2 (90mg), 2007 | ticagrelor 90 mg twice daily versus clopidogrel | patients with NSTE-ACS, treated with aspirin and standard therapy for ACS | double blind Follow-up duration: 12 weeks |
| ticlopidine versus control | |||
| STAI, 1990 | ticlopidine 250 mg b.i.d versus untreated control | patients with unstable angina <=48hrs from the pain onset | single blind Follow-up duration: 6m |
| ticlopidine versus placebo | |||
| Florida UA, 0 | Ticlopidine 500mg/d versus | Follow-up duration: 14d | |
| trapidil versus placebo | |||
| Modena, 0 | trapidil versus | Follow-up duration: 6m | |
| triflusal versus aspirin | |||
| TIM, 2000 | triflusal 600 mg daily versus aspirine 300 mg daily | AMI within less than 24 h of symptom onsete | double blind Follow-up duration: 35 days Portugal, Spain, Italy |
| triflusal versus placebo | |||
| Plaza, 1993 | triflusal 300 mg three times daily versus placebo | patients with unstable angina | double blind Follow-up duration: 6m Spain |
| UFH versus control (on top of aspirin) | |||
| Holdright, 1994 | intravenous heparin plus oral aspirin (150 mg once daily) versus aspirin alone 150 mg/d | unstable angina | single blind Follow-up duration: hospital stay |
| RISC (heparin+aspirin vs ASP), 1990 | 5 days of intermittent intravenous heparin + oral aspirin 75 mg/day versus oral aspirin 75 mg/day | unstable angina or non-Q-wave myocardial infarction | open Follow-up duration: 90 days |
| Theroux (heparin+ASP vs ASP), 1988 | aspirin 325 mg/d + heparin 1000 UI/hr IV versus aspirin 325 mg/d | double blind Follow-up duration: 3-9 days | |
| UFH versus placebo | |||
| RISC (heparin vs PBO), 1990 | 5 days of intermittent intravenous heparin versus placebo | men with unstable coronary artery disease (unstable angina or non-Q-wave myocardial infarction) | Follow-up duration: 1y (5,30 and 90 days) Sweden |
| Theroux (heparin vs PBO), 1988 | heparin (1000 units per hour by intravenous infusion) versus placebo | patients with acute unstable angina pectoris | double blind Follow-up duration: 3-9 days |
| UFH versus placebo (on top of aspirin) | |||
| Gurfinkel (UFH+aspririn vs aspirin), 1995 | aspirin plus UFH 5000 IU iv then 400 IU/kg body weight per day intravenously and titered by activated partial thromboplastin time versus aspirin 200 mg/day | patients greater than 21 years with ustable angina within 24 hours of randomizationcatio | double blind Follow-up duration: 5-7 days |
| UFH + aspirin versus placebo | |||
| RISC (ASP+ heparin vs PBO), 1990 | oral apsirin 75mg/d + intermittent IV heparin 10000UI/d followed by 7500 UI 6-hourly for 4 days versus placebo | men with unstable coronary artery disease (unstable angina or non-Q-wave myocardial infarction) | Follow-up duration: 1y (5,30 and 90 days) Sweden |
| Theroux (heparin+aspirin vs PBO), 1988 | heparin (1000 units per hour by intravenous infusion)+ aspirin (325 mg twice daily) versus aspirin (325 mg twice daily) | double blind Follow-up duration: 3-9 days | |
| UFH, warfarin versus aspirin | |||
| Cohen (ATACS pilot) (heparin vs asp), 1990 | heparin followed by warfarin (without aspirin) versus aspirin 325 mg/day | Patients between 21 and 75 years with unstable angina or non-Q-wave MI with last episode of pain within 48 hours of screening | open Follow-up duration: 12 weeks |
| UFH, warfarin versus control (on top of aspirin) | |||
| ATACS (Cohen), 1994 | aspirin 162.5 mg daily plus heparin (activated partial thromboplastin time, two times control) followed by aspirin 162.5 mg daily plus warfarin (international normalized ratio, 2 to 3) for 12 weeks. versus aspirin alone (162.5 mg daily) for 12 weeks. | patients with unstable rest angina or non-Q-wave myocardial infarction with last episode of pain within 48 hours of randomization and who were nonprior aspirin users | single blind Follow-up duration: 12 weeks |
| Cohen (ATACS pilot) (heparin+aspirin vs asp), 1990 | aspirin (80 mg/day) plus heparin and then warfarin versus aspirin (325 mg/day) | Patients between 21 and 75 years with unstable angina or non-Q-wave MI with last episode of pain within 48 hours of screening. | open Follow-up duration: 12 weeks |
| vorapaxar versus placebo (on top standard therapy) | |||
| TRACER, 2011 NCT00527943 | vorapaxar (SCH 530348) oral tablets; 40-mg loading dose on first day, followed by 2.5 mg once daily for at least 1 year
versus Placebo (added to the existing standard of care (eg, aspirin, clopidogrel) | patients with acute coronary syndrome | double-blind |
| warfarin versus aspirin | |||
| ATACS (pilot study) warfarin vs aspirin, 1990 | heparin/warfarin target INR 3-4 versus aspirin 325 mg daily | UA, NSTEMI | open Follow-up duration: 3 months |
| warfarin versus control (on top of aspirin) | |||
| ATACS (pilot study) (warfarin vs control), 1990 | heparin/warfarin target INR 3-4.5 + aspirin versus aspirin alone | UA, NSTEMI | open Follow-up duration: 3 months |
| ATACS, 1994 | heparin/warfarin (INR median 2.3) + aspirin versus aspirin | UA, NSTEMI | open Follow-up duration: 3 months |
| CARS, 1997 | warfarin (INR mean 1.5) (3 mg warfarin or 1 mg warfarin with 80 mg aspirin) versus aspirin 160 mg/d | AMI | Follow-up duration: 14 months |
| OASIS Pilot (phase 1), 1998 | warfarin 3mg/d for 6 months (INR mean 1.5) versus control | UA, NSTEMI | open Follow-up duration: 6 months |
| OASIS Pilot (phase 2), 1998 | warfarin adjusted dose (INR mean 2.3) for 3 months versus standard treatment | UA, NSTEMI | open Follow-up duration: 3 months |
| OASIS-2 Warfarin Substudy, 2001 | warfarin target INR 2–2.5 for 5 months +aspirin versus control | UA | open Follow-up duration: 5 months |
| APRICOT-2, 2002 | moderate-intensity coumarin target INR 2-3 (+aspirin) versus aspirin | STEMI | Follow-up duration: 3 months |
| CHAMP, 2002 | warfarin (INR median 1.8) versus | AMI | Follow-up duration: 2.7 years |
| WARIS, 2002 | warfarin (INR 2.2 (mean) versus | AMI | Follow-up duration: 4 years |
| LoWASA, 2004 | warfarin (prothrombin complex activity mean 95.5) versus | AMI | Follow-up duration: 5 years |
| Zibaeenezhad, 2004 | Warfarin target INR 2–3 versus | AMI | Follow-up duration: 1 year |
| warfarin versus placebo (on top of aspirin) | |||
| Williams, 1997 | warfarin target INR 2–2.5 +aspirin versus placebo +aspirin | UA, AMI | double blind Follow-up duration: 2.5 months |
| Huyhn, 2001 | warfarin adjusted dose for INR 2–2.5 +aspirin versus placebo +aspirin | UA, NSTEMI with prior CABG | double blind Follow-up duration: 1 year |
| ximelagatran versus placebo | |||
| ESTEEM, 2003 | oral ximelagatran at doses of
24 mg, 36 mg, 48 mg, or 60 mg twice daily versus placebo | patients who had had recent ST-elevation or non-STelevation myocardial infarction | double-blind Follow-up duration: 6 months |
in first
in second
-
About
-
Browse pathology
|
treatment
-
Site map
-
Credits
Made with in Lyon
-
Contact us
-
Privacy policy
-
